Literature DB >> 4006374

Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.

W T Chiang, C von Bahr, B Calissendorff, R Dahlqvist, H Emilsson, A Magnusson, K Schenck-Gustafsson.   

Abstract

The kinetics and dynamics of total and free (unbound) disopyramide (D) after dosing with D, 1.5 and 2 mg/kg iv, were compared with those of the dealkylated metabolite (MND) after dosing with MND, 0.5 and 1.5 mg/kg iv, in six healthy subjects. Dynamic parameters included ECG with measurement of the QT interval corrected for heart rate (QTc), systolic time intervals, vitamin C-stimulated saliva secretion, pupil size, and maximum accommodation capacity. Mean values of total clearance, apparent volume of distribution, and elimination t1/2 of MND were 5.9, 2.3, and 0.4 times those of total D, respectively. D significantly prolonged the QTc and systolic time intervals and induced transient inhibition of stimulated saliva secretion. In contrast, MND induced no substantial change in either the QTc or systolic time intervals, but did induce more persistent inhibition of salivary secretion. If anticholinergic potency is determined as the degree of inhibition of stimulated saliva flow per plasma concentration unit, MND was three times as potent as its parent when measured at maximum inhibition. There were no consistent drug effects on the ocular parameters. The effect of D on QTc correlated with both total and free plasma concentrations. Furthermore, its transient salivary inhibitory effect paralleled its initial rapid decline in plasma concentration. There was no relationship between the MND plasma concentration and its salivary inhibitory effect. We conclude that disopyramide significantly affected the QTc and systolic time intervals in healthy subjects, while MND in a similar dose had no such effects. MND more strongly inhibited stimulated saliva flow, indicating a more potent anticholinergic effect than D.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006374     DOI: 10.1038/clpt.1985.131

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.

Authors:  J Hasselström; M Enquist; J Hermansson; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

4.  Comparative class 1 electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans.

Authors:  L Bergfeldt; K Schenck-Gustafsson; R Dahlqvist
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

5.  Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study.

Authors:  Raffaele Coppini; Cecilia Ferrantini; Josè Manuel Pioner; Lorenzo Santini; Zhinuo J Wang; Chiara Palandri; Marina Scardigli; Giulia Vitale; Leonardo Sacconi; Pierluigi Stefàno; Laura Flink; Katherine Riedy; Francesco Saverio Pavone; Elisabetta Cerbai; Corrado Poggesi; Alessandro Mugelli; Alfonso Bueno-Orovio; Iacopo Olivotto; Mark V Sherrid
Journal:  JACC Basic Transl Sci       Date:  2019-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.